Carbonic anhydrase III: A neglected isozyme is stepping into the limelight

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 28, Issue 2, 2013, Pages 231-239

  Harju, Anna Kaisa ^a   Bootorabi, Fatemeh ^a,b   Kuuslahti, Marianne ^a,b   Supuran, Claudiu T ^c   Parkkila, Seppo ^a,b,d  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF FLORENCE   (Italy)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Enzyme; Expression; Immunohistochemistry; Muscle; PH

Indexed keywords

CARBONATE DEHYDRATASE III; ISOENZYME;

ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; GENE DELETION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE; MOLECULAR WEIGHT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SUBMANDIBULAR GLAND; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARBONIC ANHYDRASE III; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; TISSUE DISTRIBUTION;

EID: 84878551753     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2012.700640     Document Type: Review

References (76)

1. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7: 168-181.
2. Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem 2007;15:4336-4350.
3. Lehtonen J, Shen B, Vihinen M, Casini A, Scozzafava A, Supuran CT et al. Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem 2004;279:2719-2727.
4. Aspatwar A, Tolvanen ME, Parkkila S. Phylogeny and expression of carbonic anhydrase-related proteins. BMC Mol Biol 2010;11:25.
5. Taniuchi K, Nishimori I, Takeuchi T, Ohtsuki Y, Onishi S. cDNA cloning and developmental expression of murine carbonic anhydrase-related proteins VIII, X, and XI. Brain Res Mol Brain Res 2002;109:207-215.
6. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767-777.
7. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995;64:375-401.
8. Parkkila S, Parkkila AK, Rajaniemi H, Shah GN, Grubb JH, Waheed A et al. Expression of membrane-associated carbonic anhydrase XIV on neurons and axons in mouse and human brain. Proc Natl Acad Sci USA 2001;98:1918-1923.
9. Pastoreková S, Parkkila S, Parkkila AK, Opavský R, Zelník V, Saarnio J et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997;112:398-408.
10. Fujikawa-Adachi K, Nishimori I, Taguchi T, Onishi S. Human mitochondrial carbonic anhydrase VB. cDNA cloning, mRNA expression, subcellular localization, and mapping to chromosome x. J Biol Chem 1999;274:21228-21233.
11. Karhumaa P, Leinonen J, Parkkila S, Kaunisto K, Tapanainen J, Rajaniemi H. The identification of secreted carbonic anhydrase VI as a constitutive glycoprotein of human and rat milk. Proc Natl Acad Sci USA 2001;98:11604-11608.
12. Kivelä J, Parkkila S, Parkkila AK, Rajaniemi H. A low concentration of carbonic anhydrase isoenzyme VI in whole saliva is associated with caries prevalence. Caries Res 1999;33:178-184.
13. Breton S. The cellular physiology of carbonic anhydrases. JOP 2001;2:159-164.
14. Hilvo M, Rafajová M, Pastoreková S, Pastorek J, Parkkila S. Expression of carbonic anhydrase IX in mouse tissues. J Histochem Cytochem 2004;52:1313-1322.
15. Parkkila S. Significance of pH regulation and carbonic anhydrases in tumour progression and implications for diagnostic and therapeutic approaches. BJU Int 2008;101 Suppl 4:16-21.
16. Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des 2008;14:649-654.
17. Thiry A, Dogné JM, Supuran CT, Masereel B. Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem 2007;7:855-864.
18. Battke C, Kremmer E, Mysliwietz J, Gondi G, Dumitru C, Brandau S et al. Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol Immunother 2011;60:649-658.
19. Jeffery S, Carter ND, Smith A. Immunocytochemical localization of carbonic anhydrase isozymes I, II, and III in rat skeletal muscle. J Histochem Cytochem 1986;34:513-516.
20. Wade R, Gunning P, Eddy R, Shows T, Kedes L. Nucleotide sequence, tissue-specific expression, and chromosome location of human carbonic anhydrase III: the human CAIII gene is located on the same chromosome as the closely linked CAI and CAII genes. Proc Natl Acad Sci USA 1986;83:9571-9575.
21. Spicer SS, Ge ZH, Tashian RE, Hazen-Martin DJ, Schulte BA. Comparative distribution of carbonic anhydrase isozymes III and II in rodent tissues. Am J Anat 1990;187:55-64.
22. Stanton LW, Ponte PA, Coleman RT, Snyder MA. Expression of CA III in rodent models of obesity. Mol Endocrinol 1991;5:860-866.
23. Kelly CD, Carter ND, de Boer P, Jeffery S, Moorman AF, Smith A. Detection of CAIII mRNA in rat skeletal muscle and liver by in situ hybridization. J Histochem Cytochem 1991;39:1243-1247.
24. Carter N, Lönnerholm G, Meyerson B, Wistrand P. Androgenlinked control of carbonic anhydrase III expression occurs in rat perivenous hepatocytes; an immunocytochemical study. Ups J Med Sci 2001;106:67-76.
25. Shiels A, Jeffery S, Wilson C, Carter N. Radioimmunoassay of carbonic anhydrase III in rat tissues. Biochem J 1984;218:281-284.
26. Spicer SS, Ge ZH, Tashian RE, Hazen-Martin DJ, Schulte BA. Comparative distribution of carbonic anhydrase isozymes III and II in rodent tissues. Am J Anat 1990 187(1):55-64.
27. Kato K, Mokuno K. Distribution of immunoreactive carbonic anhydrase III in various human tissues determined by a sensitive enzyme immunoassay method. Clin Chim Acta 1984;141:169-177.
28. Shima K. Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease. Hokkaido Igaku Zasshi 1984;59:98-116.
29. Väänänen HK, Paloniemi M, Vuori J. Purification and localization of human carbonic anhydrase. III. Typing of skeletal muscle fibers in paraffin embedded sections. Histochemistry 1985;83:231-235.
30. Zheng A, Rahkila P, Vuori J, Rasi S, Takala T, Väänänen HK. Quantification of carbonic anhydrase III and myoglobin in different fiber types of human psoas muscle. Histochemistry 1992;97:77-81.
31. Jeffery S, Edwards Y, Carter N. Distribution of CAIII in fetal and adult human tissue. Biochem Genet 1980;18:843-849.
32. Tweedie S, Edwards Y. Mouse carbonic anhydrase III: nucleotide sequence and expression studies. Biochem Genet 1989;27:17-30.
33. Bootorabi F, Jänis J, Hytönen VP, Valjakka J, Kuuslahti M, Vullo D et al. Acetaldehyde-derived modifications on cytosolic human carbonic anhydrases. J Enzyme Inhib Med Chem 2011;26:862-870.
34. Parkkila S, Parkkila AK, Juvonen T, Lehto VP, Rajaniemi H. Immunohistochemical demonstration of the carbonic anhydrase isoenzymes I and II in pancreatic tumours. Histochem J 1995;27:133-138.
35. Ruusuvuori E, Li H, Huttu K, Palva JM, Smirnov S, Rivera C et al. Carbonic anhydrase isoform VII acts as a molecular switch in the development of synchronous gamma-frequency firing of hippocampal CA1 pyramidal cells. J Neurosci 2004;24:2699-2707.
36. Nógrádi A, Kelly C, Carter ND. Localization of acetazolamideresistant carbonic anhydrase III in human and rat choroid plexus by immunocytochemistry and in situ hybridisation. Neurosci Lett 1993;151:162-165.
37. Halmi P, Parkkila S, Honkaniemi J. Expression of carbonic anhydrases II, IV, VII, VIII and XII in rat brain after kainic acid induced status epilepticus. Neurochem Int 2006;48:24-30.
38. Syrjälä H, Vuori J, Huttunen K, Väänänen HK. Carbonic anhydrase III as a serum marker for diagnosis of rhabdomyolysis. Clin Chem 1990;36:696.
39. Väänänen HK, Takala TE, Tolonen U, Vuori J, Myllylä VV. Musclespecific carbonic anhydrase III is a more sensitive marker of muscle damage than creatine kinase in neuromuscular disorders. Arch Neurol 1988;45:1254-1256.
40. Väänänen HK, Syrjälä H, Rahkila P, Vuori J, Melamies LM, Myllylä V et al. Serum carbonic anhydrase III and myoglobin concentrations in acute myocardial infarction. Clin Chem 1990;36:635-638.
41. Beuerle JR, Azzazy HM, Styba G, Duh SH, Christenson RH. Characteristics of myoglobin, carbonic anhydrase III and the myoglobin/carbonic anhydrase III ratio in trauma, exercise, and myocardial infarction patients. Clin Chim Acta 2000;294:115-128.
42. Vuotikka P, Uusimaa P, Niemelä M, Väänänen K, Vuori J, Peuhkurinen K. Serum myoglobin/carbonic anhydrase III ratio as a marker of reperfusion after myocardial infarction. Int J Cardiol 2003;91:137-144.
43. Tu C, Chen X, Ren X, LoGrasso PV, Jewell DA, Laipis PJ et al. Interactions of active-site residues and catalytic activity of human carbonic anhydrase III. J Biol Chem 1994;269:23002-23006.
44. Carter N, Jeffery S, Shiels A, Edwards Y, Tipler T, Hopkinson DA. Characterization of human carbonic anhydrase III from skeletal muscle. Biochem Genet 1979;17:837-854.
45. An H, Tu C, Ren K, Laipis PJ, Silverman DN. Proton transfer within the active-site cavity of carbonic anhydrase III. Biochim Biophys Acta 2002;1599:21-27.
46. Elder I, Fisher Z, Laipis PJ, Tu C, McKenna R, Silverman DN. Structural and kinetic analysis of proton shuttle residues in the active site of human carbonic anhydrase III. Proteins 2007;68:337-343.
47. Duda DM, Tu C, Fisher SZ, An H, Yoshioka C, Govindasamy L et al. Human carbonic anhydrase III: structural and kinetic study of catalysis and proton transfer. Biochemistry 2005;44:10046-10053.
48. LoGrasso PV, Tu C, Chen X, Taoka S, Laipis PJ, Silverman DN. Influence of amino acid replacement at position 198 on catalytic properties of zinc-bound water in human carbonic anhydrase III. Biochemistry 1993;32:5786-5791.
49. Koester MK, Pullan LM, Noltmann EA. The p-nitrophenyl phosphatase activity of muscle carbonic anhydrase. Arch Biochem Biophys 1981;211:632-642.
50. Kim G, Selengut J, Levine RL. Carbonic anhydrase III: the phosphatase activity is extrinsic. Arch Biochem Biophys 2000;377:334-340.
51. Truppo E, Supuran CT, Sandomenico A, Vullo D, Innocenti A, Di Fiore A et al. Carbonic anhydrase VII is S-glutathionylated without loss of catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem Lett 2012;22:1560-1564.
52. Kim G, Lee TH, Wetzel P, Geers C, Robinson MA, Myers TG et al. Carbonic anhydrase III is not required in the mouse for normal growth, development, and life span. Mol Cell Biol 2004;24:9942-9947.
53. Liu M, Walter GA, Pathare NC, Forster RE, Vandenborne K. A quantitative study of bioenergetics in skeletal muscle lacking carbonic anhydrase III using 31P magnetic resonance spectroscopy. Proc Natl Acad Sci USA 2007;104:371-376.
54. Alver A, Uçar F, Keha EE, Kalay E, Ovali E. Effects of leptin and insulin on CA III expression in rat adipose tissue. J Enzyme Inhib Med Chem 2004;19:279-281.
55. Räisänen SR, Lehenkari P, Tasanen M, Rahkila P, Härkönen PL, Väänänen HK. Carbonic anhydrase III protects cells from hydrogen peroxide-induced apoptosis. FASEB J 1999;13:513-522.
56. Zimmerman UJ, Wang P, Zhang X, Bogdanovich S, Forster R. Antioxidative response of carbonic anhydrase III in skeletal muscle. IUBMB Life 2004;56:343-347.
57. Mallis RJ, Poland BW, Chatterjee TK, Fisher RA, Darmawan S, Honzatko RB et al. Crystal structure of S-glutathiolated carbonic anhydrase III. FEBS Lett 2000;482:237-241.
58. Mallis RJ, Hamann MJ, Zhao W, Zhang T, Hendrich S, Thomas JA. Irreversible thiol oxidation in carbonic anhydrase III: protection by S-glutathiolation and detection in aging rats. Biol Chem 2002;383:649-662.
59. Kuo WH, Chiang WL, Yang SF, Yeh KT, Yeh CM, Hsieh YS et al. The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci 2003;73:2211-2223.
60. Dai HY, Hong CC, Liang SC, Yan MD, Lai GM, Cheng AL et al. Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway. Mol Carcinog 2008;47:956-963.
61. Robert-Pachot M, Desbos A, Moreira A, Becchi M, Tebib J, Bonnin M et al. Carbonic anhydrase III: a new target for autoantibodies in autoimmune diseases. Autoimmunity 2007;40:380-389.
62. Du AL, Ren HM, Lu CZ, Tu JL, Xu CF, Sun YA. Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients. Autoimmunity 2009;42:209-215.
63. Vullo D, Nishimori I, Scozzafava A, Supuran CT. Carbonic anhydrase activators: Activation of the human cytosolic isozyme III and membrane-associated isoform IV with amino acids and amines. Bioorg Med Chem Lett 2008;18:4303-4307.
64. Temperini C, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. Chemistry 2006;12:7057-7066.
65. Vullo D, Innocenti A, Nishimori I, Scozzafava A, Kaila K, Supuran CT. Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines. Bioorg Med Chem Lett 2007;17:4107-4112.
66. Vullo D, Nishimori I, Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase activators: an activation study of the human mitochondrial isoforms VA and VB with amino acids and amines. Bioorg Med Chem Lett 2007;17:1336-1340.
67. Nishimori I, Onishi S, Vullo D, Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase activators: the first activation study of the human secretory isoform VI with amino acids and amines. Bioorg Med Chem 2007;15:5351-5357.
68. Pastorekova S, Vullo D, Nishimori I, Scozzafava A, Pastorek J, Supuran CT. Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines. Bioorg Med Chem 2008;16:3530-3536.
69. Temperini C, Innocenti A, Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. Bioorg Med Chem Lett 2007;17:628-635.
70. Temperini C, Scozzafava A, Puccetti L, Supuran CT. Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with L-histidine as a platform for the design of stronger activators. Bioorg Med Chem Lett 2005;15:5136-5141.
71. Biswas S, Aggarwal M, Güzel Ö, Scozzafava A, McKenna R, Supuran CT. Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms. Bioorg Med Chem 2011;19:3732-3738.
72. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A et al. Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem 2007;15:7229-7236.
73. Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions. Bioorg Med Chem Lett 2009;19:1855-1857.
74. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A et al. Carbonic anhydrase inhibitors. Cloning, characterization and inhibition studies of the cytosolic isozyme III with anions. J Enzyme Inhib Med Chem 2009;24:70-76.
75. Supuran CT, Vullo D, Manole G, Casini A, Scozzafava A. Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2004;2:49-68.
76. Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2012;17:11-15.